Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably deserving Alabama team on the sideline in favor of an SMU squad with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and banged-up Georgia like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, whose undefeated Ducks are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. Coming up short The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” First round byes Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. Automatic byes and bids made the bracket strange The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. First round matchups No. 12 Clemson at No. 5 Texas, Dec. 21: Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? No. 11 SMU at No. 6 Penn State, Dec. 21: The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. No. 10 Indiana at No. 7 Notre Dame, Dec. 20: Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner gets ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? No. 9 Tennessee at No. 8 Ohio State, Dec. 21: The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later.NoneHow Trump’s bet on voters electing him managed to silence some of his legal woes
GloRilla, Lil Wayne, Camila Cabello Will Perform During College Football Playoff WeekendMexican gangs exploit terrorist networks to orchestrate assassination attempts on Donald Trump
No. 23 Alabama women beat Alabama State 83-33 at Emerald Coast ClassicNone
None
NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global heart valve repair and replacement devices market size is estimated to grow by USD 2.58 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.08% during the forecast period. Rising competition and innovations overall heart valve repair and replacement devices market is driving market growth, with a trend towards data-oriented technologies drive growth of market. However, shortage of cardiologists poses a challenge.Key market players include Abbott Laboratories, Artivion Inc., BioStable Science and Engineering Inc., Boston Scientific Corp., Colibri Heart Valve LLC, Edwards Lifesciences Corp., JenaValve Technology Inc., LivaNova PLC, Medtronic Plc, Micro Interventional Devices Inc., Neovasc Inc., Valcare Medical, and Xeltis AG. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The Heart Valve Repair and Replacement Devices market encompasses the production and sale of devices used to treat damaged heart valves due to congenital, acquired, age-related changes, infections, heart attacks, calcific degeneration, and other heart diseases. Key heart valves include the mitral, aortic, and tricuspid valves. Damage can lead to regurgitation or stenosis, necessitating treatment through medicines, lifestyle changes, or surgical procedures. Heart failure, stroke, blood clots, and death can result from untreated diseased valves. Major players in the market include Medtronic, Edwards Lifesciences, and SCA. Trends include FDA approval of Transcatheter Aortic Valve Implantation (TAVI) and Transcatheter Mitral Valve Repair (TMVR), acquisitions, and the development of minimally invasive procedures. However, high costs and regulatory procedures, including stringency, hinder market growth. Heart valve repair and replacement devices include prosthetic valves (mechanical and biological), transcatheter heart valves, and percutaneous heart valves. Surgical procedures involve replacing the damaged valve with a prosthetic one or repairing the native valve. Diagnostic technologies aid in identifying congenital heart defects and cardiovascular diseases. Industry growth drivers include an aging population and increasing prevalence of heart disease. In the Heart Valve Repair and Replacement Devices market, data plays a significant role in the design and development of advanced valves. Manufacturers utilize data to create optimized valves that are beneficial during surgeries. Data collection is essential in the healthcare industry, enabling the production of smart and intelligent heart valves using technologies like IoT and artificial intelligence. These valves can gather, store, and analyze data, providing valuable insights to users in real-time. For instance, the FDA's recent approval of Siron's Solo Smart aortic pericardial heart valve showcases this innovation. Equipped with sensors and data transmission technologies, this valve offers real-time information to both patients and clinicians. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges The Heart Valve Repair and Replacement Devices market encompasses solutions for addressing heart valve issues, including those caused by congenital or acquired conditions, age-related changes, infections, heart attacks, calcific degeneration, and heart disease. Challenges include treating damaged valves, mitral and aortic valve regurgitation and stenosis, heart failure, stroke, and blood clots leading to death. Treatment options range from medicines and lifestyle changes to surgical procedures. Surgical procedures involve repairing or replacing diseased valves with prosthetic valves, including mechanical and biological options. Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Aortic Valve Implantation (TAVI) are minimally invasive alternatives to surgical procedures. Major players in the market include Medtronic, Edwards Lifesciences, and SCA. Regulatory procedures and their stringency impact market growth, with FDA approval and acquisitions driving industry expansion. Diagnostic technologies and minimally invasive procedures are key growth drivers for the market. High costs and regulatory procedures remain challenges. Heart valve repair and replacement devices address various heart valve conditions, including those caused by congenital heart defects and cardiovascular diseases. Mechanical valves, tissue bioprosthetic valves, transcatheter heart valves, and percutaneous heart valves are key product categories. Industry growth is driven by the increasing prevalence of heart valve diseases and the development of innovative, minimally invasive solutions. The heart valve repair and replacement market faces a significant challenge due to the shortage of skilled cardiologists. This shortage increases the risk of misdiagnosis and improper treatment, potentially harming patients. Factors contributing to this issue include the migration of trained specialists from developing countries to developed ones and the rising number of burnt-out professionals leaving the medical field. The importance of early and accurate diagnosis and treatment cannot be overstated, making it crucial to address this shortage and ensure a sufficient supply of competent professionals in the field. Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This heart valve repair and replacement devices market report extensively covers market segmentation by 1.1 Heart valve replacement devices 1.2 Heart valve repair devices 2.1 North America 2.2 Europe 2.3 Asia 2.4 Rest of World (ROW) 1.1 Heart valve replacement devices- Heart valve replacement devices are essential medical solutions for individuals with damaged heart valves. These devices are categorized into three types based on the valve material: mechanical, tissue/bioprosthetic, and transcatheter. Mechanical valves, manufactured from synthetic materials like plastic, carbon, or metal, offer durability and longevity, typically lasting about 25 years. They are suitable for patients below 65 years with valve stenosis or regurgitation and a history of atrial fibrillation. However, patients must take anticoagulants for life due to the risk of blood clots. Mechanical valves are ideal for patients with small-sized hearts and are represented by products like Medtronic Open Pivot Mechanical Heart Valves, Edwards INTUITY Elite valve system, and Carbomedics Aortic Family. Tissue/bioprosthetic valves, derived from animal tissues or human donor tissue, provide strength and a ten-year lifespan without anticoagulant consumption. They are recommended for older patients above 65 years. However, they may not be suitable for neonatal and pediatric patients due to their tendency to break down. Some popular bioprosthetic valves include Medtronic's Mosaic and Mosaic Ultra Bioprostheses and Abbott's The EPIC MITRAL STENDED TISSUE VALVE WITH LINX ANTICALCIFICATION technology. Transcatheter heart valves, designed to replace the aortic valve, are minimally invasive, requiring mild sedation and few incisions, with short hospital stays. They are beneficial for patients with aortic valve stenosis, improving their survival rate. Complications associated with transcatheter valves include bleeding, stroke, arrhythmias, kidney disease, infections, and heart attack. Boston Scientific Corporation's LOTUS Edge Aortic Valve System, JenaValve Technology's JenaValve Pericardial TAVR System, and Medtronic's Evolut PRO System are some transcatheter heart valves available in the market. The growth of the heart valve repair and replacement devices market is driven by the increasing prevalence of heart valve diseases, technological advancements, and an aging population. The demand for minimally invasive procedures and the rising awareness of heart valve replacement therapies are also contributing factors. These trends are expected to propel the growth of this market during the forecast period. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis Heart valves are essential components of the cardiovascular system, allowing the efficient flow of blood between heart chambers and the rest of the body. Damage to heart valves due to congenital defects, acquired conditions such as infections, age-related changes, heart attacks, or calcific degeneration can lead to regurgitation or stenosis, requiring treatment. Heart disease patients may first attempt medicines or lifestyle changes, but when these methods fail, heart valve repair or replacement becomes necessary. Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Replacement (TMVR) are minimally invasive procedures that have gained popularity due to their lower risk compared to open-heart surgery. The FDA has approved several heart valve repair and replacement devices, leading to numerous acquisitions and innovations in the market. Cardiovascular diseases, including heart valve damage, affect millions worldwide, driving the demand for these devices. However, their high cost and stringent regulatory procedures can limit access to some patients. Diagnostic technologies, such as echocardiography, help identify heart valve issues early, allowing for timely intervention. Heart valve repair and replacement devices are crucial for treating various heart conditions, improving patients' quality of life and longevity. The market for these devices is constantly evolving, with ongoing research and development to address the unique needs of different patient populations. Market Research Overview Heart valves are essential components of the cardiovascular system, allowing the proper flow of blood through the heart. Damage to heart valves can occur due to congenital defects, age-related changes, infections, heart attacks, calcific degeneration, and other heart diseases. Damaged valves can lead to conditions such as regurgitation or stenosis, which can result in heart failure, stroke, blood clots, and even death. Treatment options include medicines, lifestyle changes, and surgical procedures. Heart valve repair and replacement devices are used to address damaged or diseased valves. These devices include prosthetic valves, such as mechanical and biological valves, as well as transcatheter valves like TAVR and TAVI. The industry has seen significant growth due to the increasing prevalence of cardiovascular diseases and the aging population. However, high costs and regulatory procedures, including FDA approval and stringency, can hinder market growth. Heart valve repair and replacement devices are used for both surgical procedures and minimally invasive percutaneous procedures. Mechanical valves and tissue bioprosthetic valves are common types of surgical heart valves, while transcatheter heart valves and percutaneous heart valves are used for minimally invasive procedures. Industry growth drivers include the increasing number of diagnostic technologies for congenital heart defects and the development of new technologies like TMVR. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Product Heart Valve Replacement Devices Heart Valve Repair Devices Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioMalakoff, Jefferson win to set up battle of unbeatens